Measuring brain activity is a challenge in neuroscience. Unlike other medical fields, we can't directly measure the brain. This makes it difficult to develop drugs and determine their effectiveness. Objective measurements are needed to improve treatment decisions for patients.

Improving neuroscience measurements could benefit drug development. Pharmaceutical companies prefer precedents, but personalised treatments for similar patient subgroups may be more effective for brain-related conditions.

Dr Jenny Barnett co-founded Monument Therapeutics, a spin-out of Cambridge Cognition where she served as Chief Scientific Officer, focusing on developing personalised therapeutics for these underserved patient subgroups. In this episode, she tells us about her journey from psychology to CEO and we discuss the major unmet needs in the field of neuroscience.